Advertisement
MDS Nordion's primary supplier is working closely with their regulator,the Canadian Nuclear Safety Commission, to finalize and completeimplementation of their upgrade plan. At the same time, MDS Nordion is workingclosely with their global supply network to mitigate the impact of thistemporary supply issue on their customers. Based on our current information,an approval of the upgrade plan is anticipated shortly with a targeted returnto full production in mid-December. The impact of this interruption iscurrently expected to reduce EBITDA by up to approximately US $4 million inthe first quarter of 2008.
Advertisement
About MDS Nordion
MDS Nordion (www.mdsnordion.com) is a world leader in medical isotopes,radiation and related technologies. It is a business unit of MDS Inc.(TSX:MDS)(NYSE:MDZ). MDS Inc. is a global life sciences company that providesmarket-leading products and services for the development of drugs anddiagnosis and treatment of disease. We are a leading global provider ofpharmaceutical contract research, medical isotopes for molecular imaging,radiotherapeutics, and analytical instruments. MDS Inc. has more than 6,200highly skilled people in 28 countries. Find out more at www.mdsinc.com or bycalling 1-888-MDS-7222, 24 hours a day.
Forward-Looking Statement
This document contains forward-looking statements. Some forward-lookingstatements may be identified by words like "expects", "anticipates", "plans","intends", "indicates", "targeted" or similar expressions. The statements arenot a guarantee of future impact or performance and are inherently subject torisks and uncertainties. The actual impact to the Company of the maintenanceshutdown could differ materially from that currently anticipated due to anumber of factors, including, the actual timing of a return to full productionand other risk factors identified in other documents filed by the Company withCanadian and US securities regulatory authorities from time to time.
SOURCE MDS Nordion
